[1]谢艳红,冯 莉.左氧氟沙星对老年肺结核患者血清IL-6及IFN-γ水平的影响[J].医学信息,2021,34(16):118-120.[doi:10.3969/j.issn.1006-1959.2021.16.032]
　XIE Yan-hong,FENG Li.Effect of Levofloxacin on Serum IL-6 and IFN-γ Levels in Elderly Patients with Pulmonary Tuberculosis[J].Medical Information,2021,34(16):118-120.[doi:10.3969/j.issn.1006-1959.2021.16.032]
点击复制

左氧氟沙星对老年肺结核患者血清IL-6及IFN-γ水平的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年16期
页码:
118-120
栏目:
论著
出版日期:
2021-08-15

文章信息/Info

Title:
Effect of Levofloxacin on Serum IL-6 and IFN-γ Levels in Elderly Patients with Pulmonary Tuberculosis
文章编号:
1006-1959（2021）16-0118-03
作者:
谢艳红; 冯 莉
（1.黑山县全民健康保障中心结核病防治所门诊病房，辽宁 黑山 121400； 2.沈阳市中医院预防医学科，辽宁 沈阳 110004）
Author(s):
XIE Yan-hong; FENG Li
(1.Outpatient Ward of Tuberculosis Prevention and Control Institute of Heishan County National Health Insurance Center, Heishan 121400,Liaoning,China) 2.Department of Preventive Medicine,Shenyang Traditional Chinese Medicine Hospital,Shenyang 110004,Liaon
关键词:
左氧氟沙星; 老年肺结核; IL-6; IFN-γ; 痰菌转阴率
Keywords:
Levofloxacin; Elderly pulmonary tuberculosis; IL-6; IFN-γ; Sputum conversion rate
分类号:
R521
DOI:
10.3969/j.issn.1006-1959.2021.16.032
文献标志码:
A
摘要:
目的 研究左氧氟沙星对老年肺结核患者血清IL-6及IFN-γ水平的影响。方法 选取2019年10月~2020年10月我院治疗的62例老年肺结核患者为研究对象，采用随机数字表法分为对照组和观察组，各31例。对照组给予常规治疗，观察组在对照组基础上给予左氧氟沙星治疗，比较两组病灶总吸收率、炎性因子水平、痰菌转阴率以及临床不良反应发生情况。结果 观察组临床病灶总吸收率为90.32%，高于对照组的80.64%，差异有统计学意义（P＜0.05）；观察组血清IL-6、IFN-γ低于对照组，差异有统计学意义（P＜0.05）；观察组治疗后1个月痰菌转阴率为93.54%，高于对照组的77.41%，差异有统计学意义（P＜0.05）；而观察组治疗后6个月痰菌转阴率为100.00%，与对照组的96.77%比较，差异无统计学意义（P＞0.05）；观察组不良反应发生率为9.67%，与对照组的12.90%比较，差异无统计学意义（P＞0.05）。结论 左氧氟沙星治疗老年肺结核可提高病灶吸收率，降低炎症因子水平，提升痰菌转阴率，且不会增加不良反应发生率，对老年肺结核具有良好的治疗作用。
Abstract:
Objective To study the effect of levofloxacin on serum IL-6 and IFN-γ levels in elderly pulmonary tuberculosis patients.Methods A total of 62 elderly pulmonary tuberculosis patients treated in our hospital from October 2019 to October 2020 were selected as the research objects. They were divided into a control group and an observation group by random number table method, with 31 cases in each group.The control group was given conventional standard treatment, and the observation group was given levofloxacin on the basis of the control group. The total absorption rate, inflammatory factor levels, sputum conversion rate and clinical adverse reactions were compared between the two groups.Results The total absorption rate of clinical lesions in the observation group was 90.32%, which was higher than 80.64% in the control group,the difference was statistically significant(P<0.05);Serum IL-6 and IFN-γ of the observation group were lower than those of the control group,the difference was statistically significant(P＜0.05);The negative rate of sputum bacteria in the observation group one month after treatment was 93.54%, which was higher than 77.41% in the control group,the difference was statistically significant (P<0.05);The negative rate of sputum bacteria in the observation group 6 months after treatment was 100.00%, which was compared with 96.77% in the control group,the difference was not statistically significant(P>0.05);The incidence of adverse reactions in the observation group was 9.67%, compared with 12.90% in the control group,the difference was not statistically significant(P>0.05).Conclusion Levofloxacin treatment of senile tuberculosis can increase the absorption rate of lesions, reduce the level of inflammatory factors, increase the rate of sputum conversion to negative, and does not increase the incidence of adverse reactions, and has a good therapeutic effect on senile tuberculosis.

参考文献/References:

[1]何权瀛.临床医师应当充分认识现代肺结核病的特点[J].临床误诊误治,2015,28(10):1-6. [2]张威,李成俊,王洋,等.312例不典型肺结核病老年患者临床特点和治疗转归的性别差异[J].实用预防医学,2018,25(9):103-106. [3]庞学文,李晓蓉,李敬新.2009-2017年天津市老年肺结核流行特征分析[J].中国慢性病预防与控制,2018,26(9):20-23. [4]梁冰,伍红,苏静怡,等.左氧氟沙星联合抗结核化疗方案治疗复治涂阳肺结核的临床研究[J].实用医学杂志,2015,31(18):2981-2984. [5]Barczak AK,Avraham R,Singh S,et al.Systematic,multiparametric analysis of Mycobacterium tuberculosis intracellular infection offers insight into coordinated virulence[J].PLoS Pathogens,2017,13(5):e1006363. [6]何庆周,胡谦树.左氧氟沙星对肺结核患者可溶性选择素、白介素、黏附分子及肺表面活性蛋白的影响[J].海南医学院学报,2016,22(7):652-654. [7]Barbara R,Giulia D,Michael Z,et al.PknG senses amino acid availability to control metabolism and virulence of Mycobacterium tuberculosis[J].PLoS Pathogens,2017,13(5):e1006399. [8]吕若君,杨颖,白晓雪,等.α2巨球蛋白在老年肺结核患者外周血中的表达及临床意义[J].中国老年学杂志,2014,34(15):4183-4184. [9]林日暇,冯伯荣,林昌锋,等.老年肺结核患者肺部真菌感染的临床治疗分析[J].中华医院感染学杂志,2016,26(3):580-582. [10]胡琴雪.老年与非老年肺结核患者临床特征的差异研究[D].泸州:西南医科大学,2020. [11]肖兰春,陈利.左氧氟沙星治疗耐多药肺结核的临床疗效[J].中国医药科学,2017,7(6):37-39. [12]刘文广,姚志红,廖风云,等.电子支气管镜检查36例支气管色素沉着纤维化患者临床分析[J].国际呼吸杂志,2019,39(24):1853-1857. [13]Wang J,Hong JJ,Zhang PP,et al.Cryptococcal pleuritis with pleural effusion as the only clinical presentation in a patient with hepatic cirrhosis: A case report and literature review[J].Medicine (Baltimore),2019,98(28):e16354. [14]Kushima Y,Takizawa H,Machida Y,et al.Cryptococcal Pleuritis Presenting with Lymphocyte-predominant and High Levels of Adenosine Deaminase in Pleural Effusions Coincident with Pulmonary Tuberculosis[J].Intern Med,2018,57(1):115-120. [15]张威,李成俊,王洋,等.312例不典型肺结核病老年患者临床特点和治疗转归的性别差异[J].实用预防医学,2018,25(9):103-106. [16]赵延玲.左氧氟沙星联合抗结核化疗方案治疗初治涂阳肺结核的疗效观察[J].河南医学研究,2014,23(6):84-85. [17]谭剑明,季秋平,李茂清,等.胸腺肽α1辅助治疗对耐药肺结核患者免疫功能的影响[J].中国临床新医学,2015,23(6):548-551. [18]张锦萍.细胞因子在初治肺结核患者血液中表达的研究[J].社区医学杂志,2014,12(6):24-26. [19]杨宇翔,柯鹏,曾洪波,等.初治肺结核患者强化治疗前后血清中IL-2、IL-4、IL-10、IFN-γ水平变化的临床意义研究[J].数理医药学杂志,2015(3):334-335. [20]Deshpande D,Pasipanodya JG,Mpagama SG,et al.Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis[J].Clin Infect Dis, 2018,67(suppl 3):S293-S302.

相似文献/References:

[1]李秀杰.含左氧氟沙星化疗方案治疗耐利福平结核病的预后分析[J].医学信息,2019,32(02):159.[doi:10.3969/j.issn.1006-1959.2019.02.048]
　LI Xiu-jie.Prognosis Analysis of Levofloxacin-containing Chemotherapy for Rifampicin-resistant Tuberculosis[J].Medical Information,2019,32(16):159.[doi:10.3969/j.issn.1006-1959.2019.02.048]
[2]冯瑞丰.阿奇霉素治疗急性细菌性下呼吸道感染的 有效性和安全性评价[J].医学信息,2019,32(11):152.[doi:10.3969/j.issn.1006-1959.2019.11.045]
　FENG Rui-feng.Evaluation of the Efficacy and Safety of Azithromycin in the Treatment of Acute Bacterial Lower Respiratory Tract Infections[J].Medical Information,2019,32(16):152.[doi:10.3969/j.issn.1006-1959.2019.11.045]
[3]隋文峰,潘 雪.左氧氟沙星联合头孢哌酮舒巴坦治疗老年肺炎的疗效及其对肺功能的影响[J].医学信息,2020,33(06):156.[doi:10.3969/j.issn.1006-1959.2020.06.052]
　SUI Wen-feng,PAN Xue.Effect of Levofloxacin Combined with Cefoperazone Sulbactam in the Treatment of Senile Pneumonia and Its Effect on Lung Function[J].Medical Information,2020,33(16):156.[doi:10.3969/j.issn.1006-1959.2020.06.052]
[4]陈 嫈.左氧氟沙星致上消化道出血再发2例报道[J].医学信息,2021,34(08):192.[doi:10.3969/j.issn.1006-1959.2021.08.054]
[5]魏长斌.头孢哌酮钠舒巴坦钠对糖尿病合并尿路感染的疗效及安全性分析[J].医学信息,2021,34(14):151.[doi:10.3969/j.issn.1006-1959.2021.14.042]
　WEI Chang-bin.Analysis of the Efficacy and Safety of Cefoperazone Sodium and Sulbactam Sodium on Diabetes Complicated with Urinary Tract Infection[J].Medical Information,2021,34(16):151.[doi:10.3969/j.issn.1006-1959.2021.14.042]
[6]谢艳红.左氧氟沙星联合利福喷丁胶囊治疗老年初治肺结核患者的效果[J].医学信息,2021,34(17):151.[doi:10.3969/j.issn.1006-1959.2021.17.040]
　XIE Yan-hong.The Effect of Levofloxacin Combined with Rifapentine Capsule in the Treatment of Pulmonary Tuberculosis in the Elderly[J].Medical Information,2021,34(16):151.[doi:10.3969/j.issn.1006-1959.2021.17.040]
[7]张 翠,王 喆,杨悦杰,等.利福平联合多西环素及左氧氟沙星治疗布氏菌病的疗效[J].医学信息,2022,35(03):112.[doi:10.3969/j.issn.1006-1959.2022.03.027]
　ZHANG Cui,WANG Zhe,YANG Yue-jie,et al.Effect of Rifampicin Combined with Doxycycline and Levofloxacin in the Treatment of Brucellosis[J].Medical Information,2022,35(16):112.[doi:10.3969/j.issn.1006-1959.2022.03.027]
[8]曾小兰.阿莫西林-克拉维酸钾、左氧氟沙星治疗下呼吸道感染的疗效及成本-效果分析[J].医学信息,2022,35(18):77.[doi:10.3969/j.issn.1006-1959.2022.18.019]
　ZENG Xiao-lan.Efficacy and Cost-effectiveness Analysis of Amoxicillin-clavulanate Potassium and Levofloxacin in Treatment of Lower Respiratory Tract Infection[J].Medical Information,2022,35(16):77.[doi:10.3969/j.issn.1006-1959.2022.18.019]
[9]曾文宏,叶芳芳,周志明.哌拉西林钠他唑巴坦钠联合左氧氟沙星治疗慢性支气管炎的临床疗效及安全性观察[J].医学信息,2022,35(23):140.[doi:10.3969/j.issn.1006-1959.2022.23.029]
　ZENG Wen-hong,YE Fang-fang,ZHOU Zhi-ming.Observation on Clinical Efficacy and Safety of Piperacillin Sodium and Tazobactam Sodium Combined with Levofloxacin in the Treatment of Chronic Bronchitis[J].Medical Information,2022,35(16):140.[doi:10.3969/j.issn.1006-1959.2022.23.029]
[10]叶芳芳,周志明,曾文宏.哌拉西林钠他唑巴坦钠联合左氧氟沙星对支气管扩张患者气道功能、炎症反应的影响[J].医学信息,2023,36(01):103.[doi:10.3969/j.issn.1006-1959.2023.01.020]
　YE Fang-fang,ZHOU Zhi-ming,ZENG Wen-hong.Effect of Piperacillin Sodium and Tazobactam Sodium Combined with Levofloxacin on Airway Function and Inflammatory Response in Patients with Bronchiectasis[J].Medical Information,2023,36(16):103.[doi:10.3969/j.issn.1006-1959.2023.01.020]

更新日期/Last Update: 1900-01-01